F4 - Isoprostanes as Specific Marker of Docosahexaenoic Acid Peroxidation in Alzheimer's Disease

Authors

  • Jaffar Nourooz-Zadeh,

  • Edwin H. C. Liu,

  • B. Yhlen,

  • Erik E. Änggåard,

  • Barry Halliwell


  • The present address of Dr. B. Halliwell is Department of Biochemistry, National University of Singapore, Kent Ridge Crescent, Singapore, 119260.

  • Abbreviations used : AAPH, 2,2' -azobis(2-amidinopropane) ; AD, Alzheimer's disease ; BHT, butylated hydroxytoluene ; DHA, docosahexaenoic acid ; GC-MS, gas chromatography-mass spectroscopy ; NBB, N-butylboronate ; NICI, negative ion chemical ionisation ; PFB, pentafluorobenzyl bromate ; PG, prostaglandin ; PMI, postmortem interval ; TMS, trimethylsilane.

Address correspondence and reprint requests to Dr. J. Nouroozzadeh at Centre for Clinical Pharmacology and Therapeutic Toxicology, Department of Medicine, University College, 5 University Street, WC1E 6JJ, London, U.K.

Abstract

Abstract : F2-isoprostanes are prostaglandin-like compounds derived from free radical-catalysed peroxidation of arachidonic acid. Peroxidation of eicosapentaenoic acid produces F3-isoprostanes, whereas peroxidation of docosahexaenoic acid would give F4-isoprostanes. This study demonstrates the presence of esterified F4-isoprostanes in human brain and shows that levels are elevated in certain brain cortex regions in Alzheimer's disease. Our data with Alzheimer's disease suggest that analysis of F4-isoprostanes will provide new opportunities to study lipid peroxidation in the neurodegenerative diseases.

Ancillary